Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess Comparison of toxicities of PARP inhibitors (Niraparib, Olaparib, Rucaparib) used in gynaecological cancer centre

Next Previous
Trial Profile

To assess Comparison of toxicities of PARP inhibitors (Niraparib, Olaparib, Rucaparib) used in gynaecological cancer centre

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niraparib (Primary) ; Olaparib (Primary) ; Rucaparib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions

Most Recent Events

  • 09 Oct 2020 New trial record
  • 21 Sep 2020 Results (n=119) presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top